On Thursday (local time), the U.S. Food and Drug Administration (FDA) gave its nod of approval to the FL-100, a brain stimulation device designed for home use. This innovative product, crafted by the Swedish medical device firm Flow Neuroscience, is set to revolutionize depression treatment by providing an alternative to the conventional antidepressant medications. Weighing less than a pair of over-ear headphones, the FL-100 combats depression by gently delivering electrical currents to specific brain regions responsible for mood regulation.

Engineered for remote-supervised home treatment, this device stands as the first of its kind to receive FDA approval in the United States. The FL-100 is tailored for individuals aged 18 and above who are grappling with moderate to severe depression. It can be used as a standalone treatment or in conjunction with other therapies, although it is not recommended for patients with drug-resistant depression. Flow Neuroscience has outlined plans to introduce the FL-100 to the U.S. market via prescription in the second quarter of 2026, with an anticipated retail price ranging from $500 to $800.

The FDA's decision to approve the FL-100 was informed by a mid-stage clinical trial, which revealed that 58% of patients experienced a reduction in symptoms after undergoing 10 weeks of treatment. Furthermore, global user data suggests that 77% of users reported an improvement in their symptoms within just three weeks. The side effects associated with the FL-100 are generally mild and short-lived, encompassing skin irritation, headaches, and tingling sensations at the electrode contact points.